SMA Peg denied for failing step therapy by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Requires Step Therapy for Pegylated SMA Therapy — and Why You Can Challenge It

Step-therapy (also called "fail-first") denials require you to try and fail one or more alternative therapies before Anthem will cover the prescribed pegylated SMA treatment. For patients with spinal muscular atrophy, this protocol is particularly contentious because SMA is a progressive, irreversible neurodegenerative disease — a delay in appropriate therapy can mean permanent loss of motor function that cannot be recovered once gained. Courts, regulators, and external reviewers have repeatedly recognized that step-therapy requirements are inappropriate when the required prior therapy is clinically unsuitable or when delay poses unacceptable risk.

## The Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice. Request the specific step-therapy protocol in writing — Anthem must provide the criteria it used.
• Step-therapy exception request: Most states and federal guidance recognize formal step-therapy exception pathways. Ask Anthem explicitly for a "step-therapy exception" if your prescriber can document clinical contraindication, prior failure, or that the required first-step therapy is clinically inappropriate.
• External review (ACA §2719): Available after final internal denial. The approximately 4-month window (120 days) allows an independent organization to assess whether Anthem's step requirements are clinically appropriate for your specific SMA presentation. This is binding on Anthem.
• Expedited review: Request if neuromuscular deterioration is ongoing; Anthem must respond within 72 hours.
• ERISA §503: Entitles you to review all documents Anthem used to construct its step-therapy protocol.

## What to Gather

1. Diagnosis confirmation — specialist notes confirming SMA type, age of onset, and current functional status. 2. Clinical rationale for skipping the step — your prescriber must document, specifically, why the required prior therapy is clinically contraindicated, inappropriate, or already known to have failed (with dates and documented outcomes). 3. Disease progression urgency — objective motor or respiratory assessments showing active decline that makes delay medically unacceptable. 4. FDA prescribing label — the current label for the prescribed therapy, showing the approved indication and any populations for which step-through requirements may be medically unjustifiable. 5. Applicable guideline organization reference — your prescriber should note which neuromuscular disease guideline body (e.g., applicable Cure SMA or neurology society guidelines) supports first-line use in your situation.

## Criteria-Mapping Structure

Obtain Anthem's step-therapy policy (anthem.com or written request) and map each step requirement to your clinical record:

| Step Requirement | Your Chart Evidence / Exception Basis | |---|---| | Prior trial of first-step therapy | Dates of trial, documented failure or intolerance | | Clinical contraindication exception | Prescriber letter citing specific clinical reason | | SMA type/functional classification | Neuromuscular specialist note, genetic confirmation | | Prescribing specialist requirement | Physician credentials and affiliation |

The core argument: SMA is irreversible and time-sensitive. A step-therapy exception is medically warranted when the required prior therapy is not appropriate for your SMA type, age, or functional status, and the prescriber has documented that the requested therapy is the medically necessary choice per the FDA label and applicable specialty guidelines.